Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.
What it found
We found no results in the registry or in papers.
This trial finished 24 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Tizanidine
Who could take part
MS (type not specified) · 18 and over
Inclusion Criteria: * IRB approved ICF must be signed and dated by patient or patient's legal representative * Male or Female 18 years of age or older * Clinical diagnosis of established spasticity (at least 3 months) secondary to multiple sclerosis, stroke, or spinal cord injury * Currently on stable dose of up to 36mg of Zanaflex * Must be able to swallow tablets or capsules whole Exclusion Criteria: * Patients with dementia, aphasia, or other deficits in cognition * Unwilling or unable to complete cognition test or daily diary * Known sensitivity to Zanaflex * Taking Zanaflex on an as needed ("prn") basis * Currently being treated with drugs having significant effects at the alpha2 receptors whether agonist (i.e., clonidine, methyldopa) or antagonist (i.e., phenothiazines, imipramine) * Currently on any other muscle relaxant or any drugs having muscle relaxant properties (including baclofen, dantrolene, diazepam and other benzodiazepines, tranquilizers, narcotic analgesics, high dose neuroleptics, chlormezanone, meprobamate, methocarbamol, orphenadrine, carisoprodol, gabapentin and clonidine * Taking any over-the-counter or prescription sleep aids within 30 days prior to screening * Use of illegal drugs or legal drugs for recreational purposes or excessive use of alcohol * Patients suffering from disabling, symptomatic hypotension (i.e., syncope) * Patients having any systemic disease such as renal insufficiency, clinically relevant elevations in hepatic transaminase, severe, uncontrolled systemic hypertension * Any clinically significant illnesses, within four weeks of screening * Patients with known sleep disorders * Patients who participated in a clinical trial within thiry days prior to screening * Women of childbearing potential who are pregnant, have a positive serum pregnancy test, lactating, or do not or will not take adequate contraceptive precautions for the duration of trial
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This study is being conducted to compare the impact of somnolence (sleepiness) on cognition (awareness) as well as the safety and effectiveness of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride tablets) taken while in the fed state (just after a meal) and in the fasted state (before a meal) in patients with moderate to severe spasticity.
Loading reviews and guidelines…
Related trials
- ICE Trial
Phase 4 · Ongoing (inferred)
Still running
- A Study to Investigate Arbaclofen ER Tablets for the Trea…
Phase 3 · Not yet recruiting
Still running
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- ICE
Phase 4 · Recruiting
Still running
- Mechanisms of Cannabidiol in Persons With MS: the Role of…
Phase 2 · Recruiting
Still running
- AntibioBoNTA
Phase 3 · Ongoing
Still running
History
Started
Jun 2002
Finished
Sept 2002
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error